L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: An 8-week, randomized, double-blind, placebo-controlled, 2-center study

Journal of Clinical Psychiatry

Volumn 72, Issue 1, 2011, Pages 34-42

  Ritsner, Michael S ^a,b   Miodownik, Chanoch ^c   Ratner, Yael ^b   Shleifer, Tatyana ^c   Mar, Ia ^b   Pintov, Leonid ^b   Lerner, Vladimir ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THEANINE; ZIPRASIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; COGNITION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUTAMATES; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PLACEBOS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 79551525420     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05324gre     Document Type: Article

References (60)

1. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41. doi:10.1016/S0140-6736(08)61764-X
2. Tandon R, Belmaker RH, Gattaz WF, et al. Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38. doi:10.1016/j.schres.207.1.03
3. Brimble MA, Levi MS. A review of agents patented for their neuroprotective properties. Recent Patents CNS Drug Discov. 2006;1(2):139-146. doi:10.2174/157489067452758
4. Thompson PM, Bartzokis G, Hayashi KM, et al. HGDH Study Group. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex. 2009;19(5):1107-1123. doi:10.1093/cercor/bhn152
5. Ekborg-Ott KH, Taylor A, Armstrong DW. Varietal differences in the total and enantiomeric composition of theanine in tea. J Agric Food Chem. 1997;45(2):353-363. doi:10.1021/jf960432m (Pubitemid 127485933)
6. Bryan J. Psychological effects of dietary components of tea: caffeine and L-theanine. Nutr Rev. 2008;66(2):82-90. doi:10.1/j.1753-487.207.01.x (Pubitemid 351666653)
7. Nathan PJ, Lu K, Gray M, et al. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother. 2006;6(2):21-30. doi:10.130/J157v06n0202 (Pubitemid 44964090)
8. Yamada T, Terashima T, Okubo T, et al. Effects of theanine, r-glutamylethylamide, on neurotransmitter release and its relationship with glutamic acid neurotransmission. Nutr Neurosci. 2005;8(4):219-226. doi:10.1080/102841505017079 (Pubitemid 43250400)
9. Egashira N, Hayakawa K, Mishima K, et al. Neuroprotective effect of gamma-glutamylethylamide (theanine) on cerebral infarction in mice. Neurosci Lett. 2004;363(1):58-61. doi:10.1016/j.neulet.204.03.046 (Pubitemid 38639851)
10. Egashira N, Ishigami N, Pu F, et al. Theanine prevents memory impairment induced by repeated cerebral ischemia in rats. Phytother Res. 2008;22(1):65-68. doi:10.102/ptr.261 (Pubitemid 351155914)
11. Kakuda T, Yanase H, Utsunomiya K, et al. Protective effect of gammaglutamylethylamide (theanine) on ischemic delayed neuronal death in gerbils. Neurosci Lett. 2000;289(3):189-192. doi:10.1016/S0304-3940(0)01286-6 (Pubitemid 30657970)
12. 3H]kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci Biotechnol Biochem. 2002;66(12):2683-2686. doi:10.1271/b.6.2683
13. Cho HS, Kim S, Lee SY, et al. Protective effect of the green tea component, L-theanine on environmental toxins-induced neuronal cell death. Neurotoxicology. 2008;29(4):656-662. doi:10.1016/j.neuro.208.03.04
14. Lu K, Gray MA, Oliver C, et al. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol. 2004;19(7):457-465. doi:10.102/hup.61 (Pubitemid 39378268)
15. Egashira N, Hayakawa K, Osajima M, et al. Involvement of GABA(A) receptors in the neuroprotective effect of theanine on focal cerebral ischemia in mice. J Pharmacol Sci. 2007;105(2):211-214. doi:10.1254/jphs.SCZ070901 (Pubitemid 350106812)
16. Kakuda T, Nozawa A, Unno T, et al. Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat. Biosci Biotechnol Biochem. 2000;64(2):287-293. doi:10.1271/b.64.287
17. Kimura R, Murata T. Effect of theanine on norepinephrine and serotonin levels in rat brain. Chem Pharm Bull (Tokyo). 1986;34(7):3053-3057. (Pubitemid 16001865)
18. Mason R. 200 mg of Zen; L-theanine boosts alpha waves, promotes alert relaxation. Altern Complement Ther. 2001;7(2):91-95. doi:10.1089/107628015125092
19. Yokogoshi H, Kobayashi M, Mochizuki M, et al. Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res. 1998;23(5):667-673. doi:10.1023/A:102490806093 (Pubitemid 28173572)
20. Yokogoshi H, Mochizuki M, Saitoh K. Theanine-induced reduction of brain serotonin concentration in rats. Biosci Biotechnol Biochem. 1998;62(4):816-817. doi:10.1271/b.62.816
21. Yamada T, Terashima T, Kawano S, et al. Theanine, gammaglutamylethylamide, a unique amino acid in tea leaves, modulates neurotransmitter concentrations in the brain striatum interstitium in conscious rats. Amino Acids. 2009;36(1):21-27. doi:10.107/s0726-07-020-7
22. Kimura R, Murata T. Influence of alkylamides of glutamic acid and related compounds on the central nervous system, I: central depressant effect of theanine. Chem Pharm Bull (Tokyo). 1971;19(6):1257-1261.
23. Sadzuka Y, Sugiyama T, Suzuki T, et al. Enhancement of the activity of doxorubicin by inhibition of glutamate transporter. Toxicol Lett. 2001;123(2-3):159-167. doi:10.1016/S0378-4274(01)0391-5 (Pubitemid 32971722)
24. Yokozawa T, Dong E. Influence of green tea and its three major components upon low-density lipoprotein oxidation. Exp Toxicol Pathol. 1997;49(5):329-335. (Pubitemid 28012722)
25. Rey MJ, Schulz P, Costa C, et al. Guidelines for the dosage of neuroleptics. I: chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol. 1989;4(2):95-104.
26. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667. (Pubitemid 36750143)
27. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Washington, DC: Department of Health, Education and Welfare; 1976.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. (Pubitemid 18039085)
29. Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6(3):201-208. doi:10.1016/0920-964(92)903-N
30. Robbins TW, James M, Owen AM, et al. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia. 1994;5(5):266-281. (Pubitemid 24231105)
31. Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med. 1992;85(7):399-402.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
33. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2-3):247-265. doi:10.1016/j.schres.205.02. 013 (Pubitemid 40804771)
34. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci. 1980;7:233.
35. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10(3):388-398.
36. Ritsner M, Kurs R, Gibel A, et al. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005;14(7):1693- 1703. doi:10.107/s136-05-2816-9 (Pubitemid 40978478)
37. White L, Harvey PD, Opler L, et al. The PANSS Study Group. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. a multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. Psychopathology. 1997;30(5):263-274. doi:10.159/0285058
38. Fitzgerald PB, de Castella AR, Brewer K, et al. A confirmatory factor analytic evaluation of the pentagonal PANSS model. Schizophr Res. 2003;61(1):97-104. doi:10.1016/S0920-964(02)0295-5 (Pubitemid 36332144)
39. Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14(3):229-234. doi:10.1016/0920-964(94)041-6
40. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Revised Edition. New York, NY: New York Academic Press; 1977.
41. Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002;52(10):1008-1030. doi:10.1016/S06-323(02)01672-4
42. Kimura K, Ozeki M, Juneja LR, et al. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74(1):39-45. doi:10.1016/j.biopsycho.206.06.06 (Pubitemid 44781395)
43. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003;70(2):83-244. doi:10.1016/S0301-082(03)087-X
44. Eschenauer G, Sweet BV. Pharmacology and therapeutic uses of theanine. Am J Health Syst Pharm. 2006;63(1):26-30. doi:10.2146/ajhp050148
45. Kobayashi K, Nagato Y, Aoi N, et al. Effects of L-theanine on the release of α-brain waves in human volunteers. Nippon Nogeikagaku Kaishi. 1998;72:153-157. (Pubitemid 128660906)
46. Okubo T, Ozeki M, Inden T, et al. Compositions for regulating desire for smoking. http://www.freepatentsonline.com/EP1319401A1.html. 2003.
47. Ozeki M, Yao H, Okubo T, et al. Compositions for promoting sleep. http://www.freepatentsonline.com/EP1277468A1.html. 2002.
48. Hintikka J, Tolmunen T, Honkalampi K, et al. Daily tea drinking is associated with a low level of depressive symptoms in the finnish general population. Eur J Epidemiol. 2005;20(4):359-363. doi:10.107/s10654-05-0148-2 (Pubitemid 40685010)
49. Shimbo M, Nakamura K, Jing Shi H, et al. Green tea consumption in everyday life and mental health. Public Health Nutr. 2005;8(8):1300-1306. doi:10.1079/PHN205752 (Pubitemid 43151342)
50. Juneja LR, Chu DC, Okubo T, et al. L-theanine - a unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci Technol. 1999;10(6-7):199-204. doi:10.1016/S0924-24(9)04-8
51. Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62(12):1305-1312. doi:10.101/archpsyc. 62.12.1305 (Pubitemid 41746608)
52. Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21(3):167-189. doi:10.1016/S0197-2456(0)046-5
53. Rabinowitz J, Davidov O. A composite approach that includes dropout rates when analyzing efficacy data in clinical trials of antipsychotic medications. Schizophr Bull. 2008;34(6):1145-1150. doi:10.1093/schbul/sbm107
54. Nich C, Carroll KM. Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data. Drug Alcohol Depend. 2002;68(2):121-130. doi:10.1016/S0376-8716(02)01-4 (Pubitemid 35247784)
55. Salim A, Mackinnon A, Christensen H, et al. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates. Psychiatry Res. 2008;160(3):335-345. doi:10.1016/j.psychres.207.08.05
56. Leucht S, Engel RR, Bäuml J, et al. Is the superior efficacy of new generation antipsychotics an artifact of LOCF? Schizophr Bull. 2007;33(1):183-191. doi:10.1093/schbul/sbl025
57. Nestoros JN, Ban TA, Lehmann HE. Transmethylation hypothesis of schizophrenia: methionine and nicotinic acid. Int Pharmacopsychiatry. 1977;12(4):215-246. (Pubitemid 8249295)
58. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33(6):523-533. doi:10.1016/S02-3956(9)029-1
59. Rǎdulescu A. A multi-etiology model of systemic degeneration in schizophrenia. J Theor Biol. 2009;259(2):269-279. doi:10.1016/j.jtbi.209.03.024
60. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, et al. Multifunctional activities of green tea catechins in neuroprotection. modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals. 2005;14(1-2):46-60. (Pubitemid 40868983)